- Exchange: New York
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Abbott Laboratories
+ Add to WatchlistABT:US
37.8100 USD 1.2200 3.33%
Share
As of 20:04:05 ET on 05/20/2013.
More on ABT
News for Abbott Laboratories (ABT)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Google’s Page Describes Speech Malady, Funds Research
- J&J Wins Expanded Approval of Simponi for Bowel Disease
- AbbVie Science Chief to Retire With No Successor in Place
- AbbVie Profit Beats Analysts’ Estimates in First Quarter
- Pfizer’s Arthritis Drug Rejected by European Regulators
- HIV Drug Cocktail Protect Hearts of Children With Virus
- S&P 500 Stocks Biggest Weekly Changes in Target Price
- Abbott’s Profit Rose on Nutritional Product Sales
- Delayed Weaning May Reduce HIV From Breast-Feeding Women
- U.S. Stock Options With Biggest Changes in Implied Volatility
- AbbVie Said to Fire Heart Sales Force as Generics Compete
- Rigel Sinks as Arthritis Medicine Shows Mixed Results
- AstraZeneca Arthritis Medicine Has Mixed Results in Trial
- U.S. Stock Options With Biggest Changes in Implied Volatility
- St. Jude, Watson, Hasbro, AT&T: Intellectual Property
- STENTYS Enrolls First Heart Attack Patient in Pivotal U.S. Clinical Trial Published 12 hours ago
- Perdue Kidd & Vickery Wins First Humira Trial - Abbott Laboratories To Pay $2.24 Million Published May 10, 2013
- Abbott Announces CE Mark for Test to Aid Doctors with Diagnosing and Monitoring Diabetes Published May 09, 2013
- Abbott to Present at UBS Global Healthcare Conference Published May 08, 2013
- Pluristem Carving Out Distinct Niche in Orthopedic Medicine With New Clinical Trials in Rotator Cuff Repair Published May 08, 2013
- Is Your Baby Part Of A Risky Science Experiment? National Coalition Calls On Big 3 Infant Formula Brands To Remove GMO Published May 01, 2013
- TNI BioTech, Inc. Appoints Industry Veteran, Dr. Joseph Fortunak, as a Strategic Consultant Published Apr 30, 2013
- RBCC: Personalized Medicine Poised to Revolutionize Insurance & Pharmaceuticals Published Apr 30, 2013
- Abaxis Reports Financial Performance For The Fourth Quarter And Fiscal 2013 Published Apr 25, 2013
- STENTYS Revenues for the First Quarter of 2013 Up 47% Over Prior Year Published Apr 25, 2013
- Zacks Bull and Bear of the Day Highlights: Conn's, Rackspace Hosting, Abbott Laboratories, AbbVie and Nuvasive Published Apr 23, 2013
- Creabilis Awarded Prestigious European Commission FP7 Grant to Further Develop its LSE 'Topical-by-Design' Technology Published Apr 23, 2013
- Most Chinese Stocks Decline as Phone, Health-Care Companies Fall Updated 20 minutes ago
- Kasowitz Benson, Eversheds, Latham, Davis:Business of Law Updated 28 minutes ago
- Sanofi, Roll Global, Heineken, WWE: Intellectual Property Updated 28 minutes ago
- ‘Love Hormone’ Promises Safer Births After Pfizer Flop
- Actavis to Buy Warner Chilcott in Women’s Health Effort
- Royalty Pharma Raises Elan Bid to $12.50 a Share in Cash
- Vitamins That Cost Pennies a Day Seen Delaying Dementia
- XenoPort Sinks as Spasticity Drug For MS Fails in Trial
- Merck Insomnia Drug Safer at Lower Dose, FDA Staff Says
- Elan Makes Two Acquisitions for $380 Million
- China’s Stocks Rise to Seven-Week High as Trading Volumes Surge
- Japan Biotech Firms Jump as Abenomics Cash Spurs Speculation
- Lundbeck-Takeda Drug Fights Depression Better at Higher Dose
- SAC Says Cooperation With U.S. No Longer ‘Unconditional’
- Credit Swaps in U.S. Fall as Leading Indicators, Sentiment Rise
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page